Find medicine
What's new
FAQs
Latest news
EMA’s human medicines committee (CHMP) recommended 14 medicines for approval at its May 2024 meeting
Ixchiq was assessed under the OPEN framework to promote global public health
Durveqtix received support through the PRIority Medicines (PRIME) scheme due to its potential to improve patients’ quality of life
EMA publishes 2023 annual report
Outcomes of the Committee for Veterinary Medicinal Products (CVMP) meeting.
Question-and-answer document clarifies regulatory requirements for devices used in combination with medicines
Events
EudraVigilance is the EU's system for managing and analysing information on adverse reactions to medicines which have been authorised or are being studied in clinical trials in the European Economic Area (EEA) and supports the reporting and analysis of suspected adverse reactions originating from clinical trials and the post-authorisation phase of...